Search

for
Search:

Learn

2 / 801 results

learn PP405

mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

Got small bald patches they say are from stress? PP405 sprays could help bring them back to life. PP405 is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier; its registered Phase 2 trial (NCT06393452) tested it once daily in 78 adults with pattern hair loss, for safety and tolerability. It is not approved, not for sale, and has not been studied in alopecia areata or stress-related shedding.
Did you know PP405 peptides can help protect your follicles from DHT? PP405 is not a peptide and does not block DHT: it is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier, aimed at waking dormant follicles. Its registered Phase 2 trial (NCT06393452) measured safety and tolerability in 78 adults with pattern hair loss; it is not approved and not for sale.
Can applying a mask with PP405 directly to thinning areas give your scalp the push it needs? No PP405 mask exists to test: PP405 is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier, it is not an anti-DHT ingredient, and it is not on sale. Its registered Phase 2 trial (NCT06393452) measured safety, not regrowth, and a rinse-out mask is in any case the wrong format for reaching the follicle.

Research

5 / 1000+ results

research PP405 in Alopecia: An Emerging Molecule worth Investigating

January 2026 in “Journal of Community Medicine and Health Solutions”

In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

research Diagnostic Comparison: SH‑1 Molecule vs PP405 — Safety Profiles in Hair Science

June 2026 in “HAL (Le Centre pour la Communication Scientifique Directe)”

This infographic compares the safety profiles of SH‑1, a cosmetic ingredient, which showed no systemic absorption, and PP405, an investigational drug with dose-dependent systemic uptake and potential threshold breaches, highlighting differences in safety between cosmetic and investigational substances according to this report.

research LB1045 Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo

July 2024 in “Journal of Investigative Dermatology”

PP405 may help hair growth by activating hair follicle stem cells.

Review of the 2024 American Academy of Dermatology Annual Meeting

research Review of the 2024 American Academy of Dermatology (AAD) Annual Meeting

April 2024

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

research Long‐Term Use of Tralokinumab in Patients With Atopic Dermatitis: A Real‐World Multicentric Case Series

June 2025 in “International Journal of Dermatology”

In this case series conducted in Austrian dermatology clinics, tralokinumab was found to be a well-tolerated and effective long-term treatment for adults with moderate-to-severe atopic dermatitis, with improvements in eczema severity and symptom suppression maintained over up to three years.

View more "pp-405" in research →

Community Join

5 / 658 results

community Phase 3 Study for PP405 officially posted

43 upvotes 21 hours ago

PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a new mechanism of action.

community Pelage have made a new post about PP405

in Chat 17 upvotes 4 weeks ago

PP405 aims to reactivate hair follicle stem cells to promote hair growth, but its effectiveness is debated. Some users are skeptical, citing past failures of similar treatments and questioning the company's claims.

community Why PP405 may not be dead just yet

1 upvotes 1 month ago

PP405 shows promise in reactivating dormant hair follicles, with early trials indicating some success, but it is not yet a proven treatment for hair loss. Users are advised to be cautious with unverified versions, and further research is needed to confirm its effectiveness compared to treatments like minoxidil and finasteride.

community PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing

80 upvotes 1 month ago

JXL069, also known as PP405, did not lead to hair regrowth after a year of testing. The lack of results may be due to formulation issues, leading to a final attempt with an improved vehicle.

community Why you can still look forward to PP405 and JXL-069

22 upvotes 1 month ago

PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.

View more "pp-405" in community →

Clinics

2 / 3 results

Experts

— no results

Try a deeper search in experts →